Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check7 days agoChange DetectedThe study page now displays a 403 Forbidden error, replacing the usual study details with an error screen. A Home button is provided to navigate away from the blocked page.SummaryDifference21%

- Check14 days agoChange DetectedRevision number updated from v3.6.6 to v3.7.0, indicating a new page version and routine maintenance. This change does not modify study content, eligibility criteria, or any user-facing information on the page.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page's revision label was updated from v3.6.5 to v3.6.6, indicating a minor update to the Study Details page. This reflects a page metadata revision rather than modifications to the study data or eligibility criteria.SummaryDifference0.0%

- Check49 days agoChange DetectedThe page’s revision tag was updated from v3.6.4 to v3.6.5, indicating a newer release of the study details page. The visible content remains unchanged; the change reflects an internal version update.SummaryDifference0.0%

- Check63 days agoChange DetectedThe page's revision history now shows a new version, v3.6.4, superseding the previous v3.6.3. This indicates a backend/content update to the page rather than changes to the study details or results.SummaryDifference0.0%

- Check92 days agoChange DetectedThe page's revision tag was updated from v3.6.0 to v3.6.3, signaling a newer version of the study record. This update appears to be a metadata revision rather than a change to study content or functionality.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.